AB 33
Alternative Names: AB-33Latest Information Update: 20 Aug 2024
At a glance
- Originator AUTOTAC Bio
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants; Tumour suppressor protein p53 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pancreatic cancer
Most Recent Events
- 02 Aug 2024 Preclinical trials in Pancreatic cancer in South Korea (unspecified route) (AUTOTAC Bio pipeline, August 2024)
- 02 Aug 2024 AUTOTAC Bio plans preclinical studies for Pancreatic cancer in between 2025 to 2026 (Unspecified route) (AUTOTAC Bio pipeline, August 2024)
- 14 May 2024 AUTOTAC Bio has patent protection for novel P62 ligand compound and composition in USA